A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Hoosier Cancer Research Network
National Cancer Institute (NCI)
Coherus Oncology, Inc.
Genentech, Inc.
UMC Utrecht
Boston Scientific Corporation
Instituto do Cancer do Estado de São Paulo
National Institutes of Health Clinical Center (CC)
AstraZeneca